Self-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In Vivo
Overview
Authors
Affiliations
Self-amplifying replicon RNA (RepRNA) possesses high potential for increasing antigen load within dendritic cells (DCs). The major aim of the present work was to define how RepRNA delivered by biodegradable, chitosan-based nanoparticulate delivery vehicles (nanogel-alginate (NGA)) interacts with DCs, and whether this could lead to translation of the RepRNA in the DCs. Although studies employed virus replicon particles (VRPs), there are no reports on biodegradable, nanoparticulate vehicle delivery of RepRNA. VRP studies employed cytopathogenic agents, contrary to DC requirements-slow processing and antigen retention. We employed noncytopathogenic RepRNA with NGA, demonstrating for the first time the efficiency of RepRNA association with nanoparticles, NGA delivery to DCs, and RepRNA internalization by DCs. RepRNA accumulated in vesicular structures, with patterns typifying cytosolic release. This promoted RepRNA translation, in vitro and in vivo. Delivery and translation were RepRNA concentration-dependent, occurring in a kinetic manner. Including cationic lipids with chitosan during nanoparticle formation enhanced delivery and translation kinetics, but was not required for translation of immunogenic levels in vivo. This work describes for the first time the characteristics associated with chitosan-nanoparticle delivery of self-amplifying RepRNA to DCs, leading to translation of encoded foreign genes, namely influenza virus hemagglutinin and nucleoprotein.
mRNA vaccines: a new era in vaccine development.
Chandra S, Wilson J, Good D, Wei M Oncol Res. 2024; 32(10):1543-1564.
PMID: 39308511 PMC: 11413818. DOI: 10.32604/or.2024.043987.
New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome.
Demoulins T, Techakriengkrai N, Ebensen T, Schulze K, Liniger M, Gerber M Methods Mol Biol. 2024; 2786:89-133.
PMID: 38814391 DOI: 10.1007/978-1-0716-3770-8_4.
Ho H, Day R, Craig D Pharmaceutics. 2024; 16(5).
PMID: 38794324 PMC: 11125439. DOI: 10.3390/pharmaceutics16050662.
RNA Combined with Nanoformulation to Advance Therapeutic Technologies.
Lima E, Dos Santos D, Souza A, Macedo M, Bandeira M, Junior S Pharmaceuticals (Basel). 2023; 16(12).
PMID: 38139761 PMC: 10745936. DOI: 10.3390/ph16121634.
Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses.
Liu Y, Li Y, Hu Q Vaccines (Basel). 2023; 11(7).
PMID: 37514957 PMC: 10383046. DOI: 10.3390/vaccines11071142.